search
Disc Medicine
Trends
- 1
Disc Medicine is facing investor investigations following an FDA letter related to one of its drug programs. Law firms have announced probes into whether the biotech company misled shareholders about regulatory prospects. The news has drawn attention from biotech investors watching how the FDA's response could affect the company's clinical development plans and share value.
- 2Bank of America Takes $9.88 Million Stake in Disc Medicine▼Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON
Bank of America Corp DE has disclosed a new investment of $9.88 million in Disc Medicine, Inc., the biotech company traded under the ticker IRON. The institutional purchase signals continued interest in the clinical-stage biopharmaceutical firm, whose shares are drawing attention from large asset managers this reporting period.